CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Regarding our dasatinib-treated CML patient cohort, we observed an increase of the proportion of innate CD8 T-cells (Eomes+ panKIR/NKG2A+) among PBMCs.